New Actions on Actionable Mutations in Lung Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 10

PMID 37296880

Authors

Xiuning Le

Yasir Y Elamin

Jianjun Zhang

Affiliations

Soon will be listed here.

Abstract

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect patients' response to treatments [...].

Citing Articles

Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age.

Dmukauskas M, Cioffi G, Waite K, Mammoser A, Sloan A, Ma P Cancers (Basel). 2024; 16(17).

PMID: 39272844 PMC: 11394199. DOI: 10.3390/cancers16172986.

Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.

Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R Cancers (Basel). 2024; 16(5).

PMID: 38473297 PMC: 10931294. DOI: 10.3390/cancers16050935.

Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.

Kim H, Lee J, Oh I, Kim E, Yoon S, Lee S Cancers (Basel). 2024; 16(3).

PMID: 38339278 PMC: 10854608. DOI: 10.3390/cancers16030528.

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.

Provencio-Pulla M, Perez-Parente D, Olson S, Hasan H, Campos Balea B, Rodriguez-Abreu D Clin Transl Oncol. 2024; 26(6):1384-1394.

PMID: 38183584 PMC: 11108921. DOI: 10.1007/s12094-023-03362-8.

References

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

Camidge D, Doebele R, Kerr K . Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019; 16(6):341-355. DOI: 10.1038/s41571-019-0173-9. View

He R, Yang X, Li T, He Y, Xie X, Chen Q . A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas. Cancers (Basel). 2022; 14(19). PMC: 9563411. DOI: 10.3390/cancers14194664. View

Shao J, Ma J, Zhang S, Li J, Dai H, Liang S . Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images. Cancers (Basel). 2022; 14(19). PMC: 9563625. DOI: 10.3390/cancers14194823. View

Wang Q, Tian N, Zhang W, Lin Z, Shi F, Kong Y . Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients. Cancers (Basel). 2022; 14(22). PMC: 9688165. DOI: 10.3390/cancers14225638. View

Carr T, McEwen R, Dougherty B, Johnson J, Dry J, Lai Z . Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer. 2016; 16(5):319-29. DOI: 10.1038/nrc.2016.35. View

Zhao X, Chen Y, Sun X, He Z, Wu T, Wu C . Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis. Cancers (Basel). 2022; 14(17). PMC: 9454565. DOI: 10.3390/cancers14174226. View

Al-Tashi Q, Saad M, Muneer A, Qureshi R, Mirjalili S, Sheshadri A . Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. Int J Mol Sci. 2023; 24(9). PMC: 10178491. DOI: 10.3390/ijms24097781. View

Hong L, Lewis W, Nilsson M, Patel S, Varghese S, Rivera M . Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel). 2022; 14(14). PMC: 9323840. DOI: 10.3390/cancers14143473. View

10.

Wu T, Lin C . Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2022; 17(9):1063-1066. DOI: 10.1016/j.jtho.2022.06.012. View

11.

Xue J, Li B, Wang Y, Huang Z, Liu X, Guo C . Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced -Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network.... Cancers (Basel). 2022; 14(19). PMC: 9563574. DOI: 10.3390/cancers14194894. View

12.

Elamin Y, Gomez D, Antonoff M, Robichaux J, Tran H, Shorter M . Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer. 2018; 20(1):43-47. DOI: 10.1016/j.cllc.2018.09.015. View

13.

Le X, Molife C, Leusch M, Rizzo M, Peterson P, Caria N . Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2022; 14(24). PMC: 9776757. DOI: 10.3390/cancers14246127. View

14.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

15.

Tian Y, Lai Q, Zheng Y, Ying L, Wang C, Jin J . Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers (Basel). 2022; 14(3). PMC: 8834139. DOI: 10.3390/cancers14030824. View

16.

Janne P, Riely G, Gadgeel S, Heist R, Ou S, Pacheco J . Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation. N Engl J Med. 2022; 387(2):120-131. DOI: 10.1056/NEJMoa2204619. View

17.

Hong L, Negrao M, Dibaj S, Chen R, Reuben A, Bohac J . Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020; 15(9):1449-1459. DOI: 10.1016/j.jtho.2020.04.026. View

18.

Lim C, Tsao M, Le L, Shepherd F, Feld R, Burkes R . Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015; 26(7):1415-21. DOI: 10.1093/annonc/mdv208. View

19.

White M, Piotrowska Z, Stirling K, Liu S, Banwait M, Cunanan K . Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clin Lung Cancer. 2021; 22(3):201-209. PMC: 8205932. DOI: 10.1016/j.cllc.2021.01.010. View

20.

Aggarwal C, Rolfo C, Oxnard G, Gray J, Sholl L, Gandara D . Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol. 2020; 18(1):56-62. DOI: 10.1038/s41571-020-0423-x. View